# Safety Study of CAT-8015 Immunotoxin in Patients With CLL, PLL or SLL With Advance Disease

> **NCT00457860** · PHASE1 · UNKNOWN · sponsor: **Cambridge Antibody Technology** · enrollment: 50 (—)

## Conditions studied

- Leukemia

## Interventions

- **DRUG:** Immunotoxin therapy
- **DRUG:** CAT-8015 immunotoxin
- **PROCEDURE:** Biological therapy

## Key facts

- **NCT ID:** NCT00457860
- **Lead sponsor:** Cambridge Antibody Technology
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2007-03
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 50 (—)
- **Last updated:** 2007-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00457860

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00457860, "Safety Study of CAT-8015 Immunotoxin in Patients With CLL, PLL or SLL With Advance Disease". Retrieved via MORVS 2026-10-26 from https://api.morvs.ai/clinical/NCT00457860. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*